에 대한 최신 뉴스 Kazia Therapeutics (NASDAQ:KZIA) 주식

Kazia Therapeutics

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics Ltd

Lands' End (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LE#NASDAQ">LE</a>) affirms FY2025 Adj EPS guidance from $0.48-$0.86 to $0.48-$0.86 vs $0.70 analyst estimate. Affirms FY2025 sales outlook from $1.33 billion-$1.45 billion to $1.33 billion-$1.45 billion vs $1.38 billion estimate.

News

Guidance

Lands' End Affirms FY2025 Adj EPS Guidance of $0.48-$0.86 vs $0.70 Est; Affirms FY2025 Sales Guidance of $1.33B-$1.45B vs $1.38B Est

WEC Energy Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEC#NYSE">WEC</a>) today announced that it intends to offer, subject to market and other conditions, $700,000,000 in aggregate principal amount of its convertible senior notes due 2028 (the "convertible notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). In addition, WEC Energy Group expects to grant the initial purchasers of the convertible notes an option to purchase, within a 13-day period beginning on, and including, the date the convertible notes are first issued, up to an additional $105,000,000 in aggregate principal amount of the convertible notes.
Final terms of the convertible notes, including the initial conversion price, interest rate and certain other terms of the convertible notes, will be determined at the time of pricing. The convertible notes will be senior, unsecured obligations of WEC Energy Group. Interest on the convertible notes will be paid semiannually. The convertible notes will mature on June 1, 2028, unless earlier converted or repurchased in accordance with their terms.

WEC Energy Group To Offer $700M In Convertible Senior Notes Due 2028

<a href="https://www.wsj.com/business/deals/kimberly-clark-nears-roughly-3-5-billion-sale-of-international-tissue-business-299c17d5?gaa_at=eafs&amp;gaa_n=ASWzDAjSvKABkZwdMZIlTw9bF1iQ-xg3hR4smhv0WaEGnmr5yNzjP-HQI5_P9Nh_BxA%3D&amp;gaa_ts=68417938&amp;gaa_sig=XyWw5OpGvoofdTyiG2em5A_2d9_UyLB2-_F6t3jzNLB5rcYATr0BmKEphk4lteRrOHONpiTBJIhBhORH8pDuTw%3D%3D" title="https://www.wsj.com/business/deals/kimberly-clark-nears-roughly-3-5-billion-sale-of-international-tissue-business-299c17d5?gaa_at=eafs&amp;gaa_n=ASWzDAjSvKABkZwdMZIlTw9bF1iQ-xg3hR4smhv0WaEGnmr5yNzjP-HQI5_P9Nh_BxA%3D&amp;gaa_ts=68417938&amp;gaa_sig=XyWw5OpGvoofdTyiG2em5A_2d9_UyLB2-_F6t3jzNLB5rcYATr0BmKEphk4lteRrOHONpiTBJIhBhORH8pDuTw%3D%3D">https://www.wsj.com/business/deals/kimberly-clark-nears-roughly-3-5-billion-sale-of-international-tissue-business-299c17d5?gaa_at=eafs&amp;gaa_n=ASWzDAjSvKABkZwdMZIlTw9bF1iQ-xg3hR4smhv0WaEGnmr5yNzjP-HQI5_P9Nh_BxA%3D&amp;gaa_ts=68417938&amp;gaa_sig=XyWw5OpGvoofdTyiG2em5A_2d9_UyLB2-_F6t3jzNLB5rcYATr0BmKEphk4lteRrOHONpiTBJIhBhORH8pDuTw%3D%3D</a>

Asset Sales

The Wall Street Journal Reported Wednesday, Kimberly-Clark Nears Roughly $3.5B Sale of International Tissue Business

AI chatbots for regular folks, human beings for VIPs: that seems to be Klarna's policy, based on CEO Sebastian Siemiatkowski's recent remarks.
What Happened: Speaking <a href="https://techcrunch.com/2025/06/04/klarna-ceo-says-company-will-use-humans-to-offer-vip-customer-service/">at</a> the London SXSW, Siemiatkowski noted that Klarna has reduced its workforce from 5,500 to approximately 3,000 <a href="https://www.benzinga.com/25/05/45590327/klarna-reduces-workforce-by-40-attributes-some-of-shrinkage-to-its-investment-in-ai">after AI came into the picture</a>.
"We can use AI to automatically take away boring jobs, things that are manual work," he said. He added that with lower salary expenses, the company now plans to redirect much of those savings toward increasing employee pay and equity incentives.
He went on to highlight Klarna's differentiated approach to regular customer support and premium service. "We think offering human customer service is always going to be a VIP thing," he said, drawing parallels to the way people pay more for handmade goods.
"We can do both—lean on AI to handle the repetitive stuff while still promising our customers a human connection when it really matters."
See Also: <a href="https://www.benzinga.com/markets/tech/25/06/45785227/chief-ai-scientist-at-mark-zuckerbergs-meta-says-no-way-scaling-chatgpt-like-models-is-going-to-lead-to-human-level-ai">Chief AI Scientist At Mark Zuckerberg&#8217;s Meta Says &#8216;No Way&#8217; Scaling ChatGPT-Like Models Is Going To Lead To Human-Level AI</a>
Why It Matters: Siemiatkowski's recent comments come after he noted last month that "from a brand perspective", it is "critical" for the customer to know <a href="https://www.benzinga.com/news/25/05/45484749/after-firing-700-humans-for-ai-klarna-now-wants-them-back-tons-of-klarna-users-would-enjoy-working-for-us-says-ceo">"that there will be always a human if you want."</a> This is a shift from the company's earlier move to solely use AI chatbots to handle customer interactions, which proved to be challenging.
Venture Capitalist Chamath Palihapitiya <a href="https://www.benzinga.com/25/05/45371290/chamath-palihapitiya-questions-ai-funding-after-swedish-bnpl-firm-klarna-rolls-back-ai-bets-startups-could-pivot-to-simply-use-ai-for-narrow-use-cases">responded to this shift</a> by observing that such challenges could lead startups to "pivot to simply use AI for narrow use cases."
In the case of Klarna, the pivot seems to be towards drawing a line between what regular customers are provided and premium services for VIPs.
"Humans are more expensive, and rich people are willing and able to pay for them," <a href="https://www.nytimes.com/2019/03/23/sunday-review/human-contact-luxury-screens.html">wrote</a> NYT tech reporter Nellie Bowles. Milton Pedraza, chief executive of the Luxury Institute, said, "What we are seeing now is the luxurification of human engagement."
Commenting on the intrinsic value of human connection, he said, "The positive behaviors and emotions human engagement elicits — think the joy of a massage. Now education, health care stores, everyone, is starting to look at how to make experiences human. The human is very important right now."
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45786038/amazon-expands-cloud-ai-footprint-with-10-billion-data-center-investment-in-north-carolina">Amazon Expands Cloud, AI Footprint With $10 Billion Data Center Investment In North Carolina</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

AI For The Masses, Humans For The Elite: Klarna CEO Details Dual-Tier Strategy Amid Growing Demand For Human Connection

BrightView Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BV#NYSE">BV</a>) ("BrightView") today announced the pricing of an underwritten secondary offering by a selling stockholder affiliated with KKR &amp; Co. Inc. (the "Selling Stockholder") of 11,600,000 shares of common stock of BrightView pursuant to a registration statement filed by BrightView with the U.S. Securities and Exchange Commission (the "SEC"). No shares are being sold by BrightView. The Selling Stockholder will receive all of the proceeds from this offering. The offering is expected to close on June 6, 2025, subject to customary closing conditions. The size of the offering reflects an increase from the 10,000,000 shares of common stock originally proposed to be sold.

Offerings

BrightView Investor KKR Upsizes Stock Sale to 11.6M Shares (From Prior 10M), Offering Closes June 6

Lands' End (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LE#NASDAQ">LE</a>) reported quarterly losses of $(0.18) per share which met the analyst consensus estimate. This is a 10 percent increase over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $261.21 million which missed the analyst consensus estimate of $272.60 million by 4.18 percent. This is a 8.50 percent decrease over sales of $285.47 million the same period last year.

Earnings

Earnings Misses

Lands' End Q1 Adj. EPS $(0.18), Inline, Sales $261.21M Miss $272.60M Estimate

APP rises over 15 points in the session
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/04230651/Screenshot-2025-06-04-at-7.04.06%E2%80%AFPM-1015x1024.png" alt="" class="wp-image-13890" /></figure>
Applovin Corp. (APP) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.&nbsp;
Today, at 10:03 AM on June 4th, a significant trading signal occurred for Applovin Corp. (APP) as it demonstrated a Power Inflow at a price of $401.10. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Applovin's stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Applovin's stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock's overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for APP, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like <a href="https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_June2025">https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_June2025</a>, which are responsible for parts of the data within this article.
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved
After Market Close, UPDATE: The price at the time of the Power Inflow was $401.10. The returns on the High price ($417.43) and Close price ($416.43) after the Power Inflow are respectively 4.1% and 3.8%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite.
Past Results are Not Indicative of Future Results
.

Equities

Technicals

Opinion

Signals

Trading Ideas

AppLovin Stock Rises 4.1% After Key Trading Signal

TD Securities analyst Andrew Charles maintains Wingstop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) with a Buy and raises the price target from $330 to $400.

Price Target

Analyst Ratings

WING

TD Securities Maintains Buy on Wingstop, Raises Price Target to $400

<ul>
<li>Record Eurobonds ADV of $2.9 Billion on 116% Increase in Block Trading and 500% Increase in Portfolio Trading ADV</li>
</ul>
Client-Initiated
<ul>
<li>Strong increases in block trading ADV across U.S. credit (+41%), emerging markets (+24%) and eurobonds (+116%). We launched our targeted block trading solution in U.S. credit in mid-May.
<ul>
<li>Block trading in emerging markets and eurobonds both benefitted from the launch of our targeted block solution in late 2024, which has generated cumulative trading volume of approximately $1.7 billion and $2.7 billion,respectively,since launch.</li>
</ul>
</li>
<li>Clients continued to leverage our algos in U.S. government bond trading, helping to drive a 57% increase in ADV to $28.3 billion with estimated market share of 2.6% in May.</li>
</ul>
Portfolio Trading
<ul>
<li>Year-to-date May 2025, estimated market share of U.S. credit portfolio trading is 18.6%, compared to 14.1% in the prior year same period, an increase of approximately 450 basis points.2
<ul>
<li>90% of all portfolio trading ADV was executed over X-Pro in May.</li>
</ul>
</li>
</ul>
Dealer-Initiated
<ul>
<li>Dealer-initiated ADV increased 41% to $1.8 billion.</li>
</ul>

General

MKTX

MarketAxess Announces Trading Volume Statistics For May 2025 With 44% Increase in Total ADV Driven by 22% Increase in Total Credit ADV and 59% Increase in Total Rates ADV

Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) sharp rise to an all-time high of $111,800 has entered a decisive phase, as data from Glassnode reveals intensified profit-taking <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45652549/vice-president-jd-vance-predicts-100m-bitcoin-holders-the-us-ought-to-be-leaning-into-bitcoin">by long-term holders</a>.
What Happened: The surge, initially driven by aggressive spot buying, is now encountering persistent sell pressure from earlier market participants, posing a critical test of the market's resilience.
Glassnode's on-chain analysis <a href="https://insights.glassnode.com/the-week-onchain-week-22-2025/?utm_campaign=WoC_22_25&amp;utm_medium=email&amp;utm_source=newsletter">released</a> on Thursday shows that key support levels at $103,700 and $95,600 will likely determine whether bullish momentum can be sustained.
"With key support at $103.7k and $95.6k, and signs of older investors offloading, the bulls now face a critical test of their resolve," the report states.
While the current cycle has delivered multiple high-profit waves, the latest realized profits peaked at $1.47 billion per day, marking the fifth major sell event of this rally. 
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45775027/pump-funs-1b-token-plan-risks-undermining-solana-defi-fueling-meme-coin-scams-experts-warn">Pump.fun&#8217;s $1B Token Plan Risks Undermining Solana DeFi, Fueling Meme Coin Scams, Experts Warn</a>
Notably, the majority of this selling is being led by investors holding Bitcoin for over a year, indicating that this is not driven by speculative short-term traders but by conviction-led capital rotation.
Historical accumulation zones, previously demand-heavy, have flipped into active distribution zones, particularly among holders who bought in the $25K–$31K and $60K–$73K ranges. 
Why It Matters: The shift signals a deeper market rotation, where seasoned holders are choosing to de-risk rather than bet on further upside.
Cost basis and statistical models further highlight $103,700 and $95,600 as critical supports. 
A breakdown below these levels, particularly without a strong demand-side catalyst, could indicate broader trend exhaustion. 
Meanwhile, the resistance ceiling remains at $114,800.
Short-term holder behavior also plays a role. The average cost basis for recent buyers sits at $97,100. If Bitcoin trades below this threshold for an extended period, it could challenge bullish sentiment among newer participants.
Glassnode also notes that the profit-taking behavior has become more measured compared to prior bull cycles. While still intense, this regime suggests maturing investor psychology and decreasing speculative excess. 
The current cycle shows lower realized profit as a percentage of market cap compared to previous tops, reinforcing the idea of more structured capital flows.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45772954/can-bitcoin-boost-portfolio-returns-without-increasing-risk-bitwises-matt-hougan-says-it-can">Can Bitcoin Boost Portfolio Returns Without Increasing Risk? Bitwise&#8217;s Matt Hougan Says It Can</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Bull Run On The Brink As Long-Term Holders Accelerate Profit-Taking: Report

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4443060-1&amp;h=4233216002&amp;u=https%3A%2F%2Fimux.com%2F&amp;a=Immunic%2C+Inc.">Immunic, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMUX#NASDAQ">IMUX</a>),&nbsp;a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced the completion of enrollment for both phase 3 ENSURE trials of lead asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with relapsing multiple sclerosis and additional phase 2 CALLIPER trial data in patients with progressive multiple sclerosis underlining the recently released positive top-line results.
Additional Data Available from Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis (PMS)
Building on the recently released data showing reductions in the relative risk of 24-week confirmed disability worsening (24wCDW) events based on the Expanded Disability Status Scale (EDSS) at the end of the main treatment period, newly available data for the secondary endpoint of time to 24wCDW based on the EDSS further reinforces the neuroprotective potential of vidofludimus calcium. In the overall PMS patient population (n=467), vidofludimus calcium demonstrated a clinically meaningful reduction of the hazard ratio (HR) for 24wCDW by 24% compared to placebo (HR 0.76). Further analyses by disease subtype showed that vidofludimus calcium was associated with a 33% reduction in 24wCDW in the primary progressive multiple sclerosis (PPMS) study population (n=152) compared to placebo (HR 0.67), a 19% reduction in the non-active secondary progressive multiple sclerosis (naSPMS) study population (n=268) compared to placebo (HR 0.81), and a 34% reduction in the active secondary progressive multiple sclerosis (aSPMS) study population (n=47) compared to placebo (HR 0.66).
Similarly, consistent with the recent top-line data, further analyses of subpopulations – both with and without inflammatory gadolinium-enhanced lesion activity at baseline, who are largely shown to not benefit from current anti-inflammatory therapies – continued to demonstrate promising results. For the overall population, vidofludimus calcium reduced 24wCDW in patients without evidence of gadolinium-enhancing lesions at baseline by 34% compared to placebo (HR 0.66). Encouraging results were likewise observed for the PPMS (reduction in 24wCDW: 35%; HR 0.65) and naSPMS (reduction in 24wCDW: 30%; HR 0.70) study populations compared to placebo.

IMUX

Immunic Announces Addl Data From Phase 2 CALLIPER Trial In Progressive MS, Supporting Recently Released Top-Line Results and Underlining Vidofludimus Calcium's Neuroprotective Potential

Needham analyst Mike Cikos reiterates MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) with a Buy and maintains $270 price target.

Reiteration

Needham Reiterates Buy on MongoDB, Maintains $270 Price Target

WestPark Capital analyst Casey Ryan reiterates CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) from Hold to Hold.

CRWD

WestPark Capital Reiterates Hold on CrowdStrike Holdingsto Hold

Updated 2025 Guidance
Vermilion is adjusting its 2025 capital budget to a range of $630 to $660 million, reflecting a reduction of approximately $100 million from the mid-point of our previous capital budget range of $730 to $760 million. This reduction reflects the removal of all remaining E&amp;D capital associated with the Saskatchewan and United States divested assets post-closing. Vermilion expects full year and second half 2025 production to range between 117,000 to 122,000 boe/d, 68% natural gas-weighted in the second half of 2025. On a go-forward basis, it is estimated that over 90% of production will come from our global gas portfolio and over 80% of capital is expected be allocated to these assets. Vermilion will continue to evaluate capital investment levels during this period of increased volatility and will adjust capital if necessary to prioritize free cash flow over production growth during 2025 and 2026.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Category</td>
<td colspan="1" rowspan="1">
Original
2025 Guidance&#x2A;
</td>
<td colspan="1" rowspan="1">
Post-Westbrick
2025 Guidance&#x2A;
</td>
<td colspan="1" rowspan="1">
Updated&nbsp;
2025 Guidance&#x2A;
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Production (boe/d)</td>
<td colspan="1" rowspan="1">84,000 – 88,000</td>
<td colspan="1" rowspan="1">125,000 – 130,000</td>
<td colspan="1" rowspan="1">117,000 – 122,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">% Natural Gas</td>
<td colspan="1" rowspan="1">56&nbsp;%</td>
<td colspan="1" rowspan="1">62&nbsp;%</td>
<td colspan="1" rowspan="1">65&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">E&amp;D capital expenditures ($MM)</td>
<td colspan="1" rowspan="1">$600 – 625</td>
<td colspan="1" rowspan="1">$730 – 760</td>
<td colspan="1" rowspan="1">$630 – 660</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Royalty rate (% of sales)</td>
<td colspan="1" rowspan="1">8 – 10%</td>
<td colspan="1" rowspan="1">9 – 11%</td>
<td colspan="1" rowspan="1">8 – 10%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Operating ($/boe)</td>
<td colspan="1" rowspan="1">$17.00 – 18.00</td>
<td colspan="1" rowspan="1">$13.50 – 14.50</td>
<td colspan="1" rowspan="1">$13.00 – 14.00</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Transportation ($/boe)</td>
<td colspan="1" rowspan="1">$3.50 – 4.00</td>
<td colspan="1" rowspan="1">$3.00 – 3.50</td>
<td colspan="1" rowspan="1">$3.00 – 3.50</td>
</tr>
<tr>
<td colspan="1" rowspan="1">General and administration ($/boe)&#x2A;&#x2A;</td>
<td colspan="1" rowspan="1">$2.75 – 3.25</td>
<td colspan="1" rowspan="1">$2.25 – 2.75</td>
<td colspan="1" rowspan="1">$2.25 – 2.75</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Cash taxes (% of pre-tax FFO)</td>
<td colspan="1" rowspan="1">7 – 9%</td>
<td colspan="1" rowspan="1">6 – 10%</td>
<td colspan="1" rowspan="1">4 – 8%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Asset retirement obligations settled ($MM)</td>
<td colspan="1" rowspan="1">$60</td>
<td colspan="1" rowspan="1">$60</td>
<td colspan="1" rowspan="1">$60</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Payments on lease obligations ($MM)</td>
<td colspan="1" rowspan="1">$20</td>
<td colspan="1" rowspan="1">$20</td>
<td colspan="1" rowspan="1">$15</td>
</tr>
</tbody>
</table>
</figure>

Commodities

Markets

Vermilion Energy Adjusts 2025 Capital Budget To $630M-$660M, Reflecting A Reduction Of Approximately $100M From The Mid-point Of Previous Capital Budget Of $730M-$760M

Contracts

IperionX On Wednesday Announced Award Of U.S. Department Of Defense SBIR Phase III Contract For Up To $99M

– Enrollment Completed for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected End of 2026 –
– Additional Data from Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis Further Supports the Recently Released Positive Top-Line Results and Further Underlines Vidofludimus Calcium's Neuroprotective Potential –
– New CALLIPER Data Regarding Time to 24-Week Confirmed Disability Worsening Shows Substantial and Medically Relevant Reductions for Vidofludimus Calcium Over Placebo in the Overall Study Population and Major Disease Subtypes –
NEW YORK, June 5, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4443060-1&amp;h=4233216002&amp;u=https%3A%2F%2Fimux.com%2F&amp;a=Immunic%2C+Inc.">Immunic, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMUX#NASDAQ">IMUX</a>),&nbsp;a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced the completion of enrollment for both phase 3 ENSURE trials of lead asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with relapsing multiple sclerosis and additional phase 2 CALLIPER trial data in patients with progressive multiple sclerosis underlining the recently released positive top-line results.
Enrollment Completed for Both Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis (RMS)
The ENSURE program comprises two identical multicenter, randomized, double-blind phase 3 trials designed to evaluate the efficacy, safety and tolerability of vidofludimus calcium versus placebo in RMS patients. Each of the trials, titled ENSURE-1 and ENSURE-2, enrolled adult patients with active RMS at more than 100 sites in 15 countries, including the United States, India and countries in the Middle East and North Africa (MENA) region, Latin America, and Central and Eastern Europe. In total, 1,121 patients in ENSURE-1 and 1,100 patients in ENSURE-2 have been randomized in a double-blinded fashion to either 30 mg daily doses of vidofludimus calcium or placebo. The primary endpoint for both trials is time to first relapse up to 72 weeks. Secondary endpoints include time to confirmed disability worsening based on the Expanded Disability Status Scale (EDSS), volume of new T2-lesions, time to sustained clinically relevant changes in cognition, and magnetic resonance imaging (MRI)-based endpoints.

Immunic Completes Enrollment For Both Phase 3 ENSURE Trials Of Vidofludimus Calcium In Relapsing Multiple Sclerosis; Top-Line Data Expected End Of 2026

<ul>
<li>$177 million in total consideration subject to customary fees and adjustments</li>
<li>Industrial, utility and data center power demand is increasing globally</li>
<li>B&amp;W now well-capitalized and poised to leverage growth in 2025 and beyond</li>
</ul>

B&W Announces Sale Of Diamond Power To ANDRITZ For $177M , Eyes Growth In Data Center And Utility Markets

Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNXT#NASDAQ">RNXT</a>) with a Buy and raises the price target from $11 to $11.5.

RNXT

Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $11.5

Life Time Group Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTH#NYSE">LTH</a>) ("Life Time" or the "Company") announced today that certain affiliates of Leonard Green &amp; Partners, L.P. and TPG Inc. (the "Selling Stockholders") intend to offer and sell 20,000,000 shares of the Company's common stock in an underwritten public offering pursuant to Life Time's shelf registration statement filed with the Securities and Exchange Commission (the "SEC"). The Selling Stockholders will receive all of the proceeds from the proposed offering. The Company will not receive any of the proceeds from the sale of shares of the Company's common stock by the Selling Stockholders. Following the consummation of the offering, the Company's voting group, which includes the Selling Stockholders, will hold approximately 43.1% of the Company's common stock.

Life Time Shareholders Leonard Green, TPG to Sell 20M Shares in Public Offering

Net proceeds from the Transaction will be directed towards debt repayment to further accelerate deleveraging efforts and strengthen Vermilion's balance sheet. Based on current strip commodity pricing(1) and operational plans, we would expect to exit 2025 with net debt(2) of $1.3 billion, with a trailing net debt to FFO ratio(3) of 1.3 times.
The Assets consist of approximately 5,500 boe/d (81% oil and liquids) of production and approximately 10 mmboe of Proved Developed Producing reserves estimated as evaluated by McDaniel &amp; Associates Consultants Ltd. at December 31, 2024. The Transaction has an effective date of January 1, 2025 and is anticipated to close in Q3 2025, subject to the satisfaction of other customary closing conditions. The Transaction agreement includes $10 million of contingent payments(4) based on WTI prices over the two-year period starting July 1, 2025.
This Transaction, combined with the sale of our East Finn assets in 2023, completes our exit from the United States, allowing us to focus on our core gas-weighted assets in Canada and Europe. Vermilion would like to sincerely thank our talented and dedicated field teams in Wyoming for their commitment to safe and efficient operations over the past 11 years as well as the technical teams, which provided support from Denver and Calgary.

Vermilion Energy Agrees To Sell Its United States Assets For $120M

Press Releases

Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme

Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium

Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA

Kazia Therapeutics Announces $2.0 Million Registered Direct Offering

Small Cap

Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering

Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer

Peraso Inc. (NASDAQ: PRSO): The Only Pure-Play mmWave Stock Poised for Growth – More Stocks Inside

Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's Disease

Comments

Kazia Therapeutics

뉴스

에 대한 최신 뉴스 Kazia Therapeutics (NASDAQ:KZIA) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌